ADVAIR DISKUS ADVAIR - GlaxoSmithKline
ADVAIR DISKUS ADVAIR - GlaxoSmithKline
ADVAIR DISKUS ADVAIR - GlaxoSmithKline
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Over the 3 year treatment period of study SCO30003, FEV 1 values were also higher in<br />
patients treated with <strong>ADVAIR</strong> ® <strong>DISKUS</strong> ® 50/500 mcg than for those treated with<br />
placebo (average difference over 3 years 92 mL, 95% CI: 75 to 108 mL; p < 0.001).<br />
<strong>ADVAIR</strong> ® <strong>DISKUS</strong> ® was also more effective than salmeterol or fluticasone propionate<br />
in improving FEV 1 (average difference over 3 years 50 mL, p < 0.001 for salmeterol and<br />
44 mL, p < 0.001 for fluticasone propionate). Averaged over the 3 years of the study,<br />
patients treated with <strong>ADVAIR</strong> ® <strong>DISKUS</strong> ® showed a +29 mL increase from baseline in<br />
post-bronchodilator FEV 1 while the placebo, salmeterol and fluticasone propionate<br />
groups demonstrated a decline of -62 mL, -21 mL, and -15 mL, respectively.<br />
TOXICOLOGY<br />
Note: For complete information on the toxicology of the individual compounds<br />
salmeterol xinafoate and fluticasone propionate, please refer to the SEREVENT ® and<br />
FLOVENT ® Product Monographs.<br />
Acute Toxicity<br />
The experimental details of single dose studies are presented below:<br />
Species<br />
(strain)<br />
Route of<br />
Administration<br />
Nominal Exposure<br />
Concentrations (mcg/L)<br />
(Salmeterol xinafoate:<br />
Fluticasone propionate)<br />
Initial<br />
Group<br />
M<br />
F<br />
Duration<br />
of Treatment<br />
(Days)<br />
Rat<br />
(Wistar)<br />
Inhalation<br />
(dry powder)<br />
0:0<br />
75:40<br />
0:0<br />
10:20<br />
20:40<br />
10 10<br />
10 10<br />
5 5<br />
5 5<br />
5 5<br />
1<br />
Rat<br />
(Wistar)<br />
Inhalation<br />
(dry powder)<br />
0:0<br />
1:2<br />
2:4<br />
5:10<br />
10:20<br />
20:40<br />
7 7<br />
7 7<br />
7 7<br />
7 7<br />
7 7<br />
7 7<br />
1<br />
Rat<br />
(Wistar)<br />
Inhalation<br />
(dry power)<br />
0:0<br />
75:0<br />
75:40<br />
10 0<br />
10 0<br />
10 0<br />
1<br />
High single inhaled doses of combinations of salmeterol xinafoate and fluticasone<br />
propionate were well-tolerated by rats. With one exception (mild atrial myocarditis), all<br />
findings were expected at the doses of salmeterol xinafoate and fluticasone propionate<br />
administered.<br />
Mild atrial myocarditis occurred at combination doses of 28 mcg/kg salmeterol with<br />
73 mcg/kg fluticasone propionate, or higher, at which plasma drug concentrations were at<br />
least 30 times (salmeterol) or 26 times (fluticasone propionate) greater than peak levels in<br />
July 29, 2014<br />
Page 48 of 67